A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SR1375 in Hospitalized Adult Patients With Community-acquired Pneumonia
Latest Information Update: 17 Apr 2025
At a glance
- Drugs SR 1375 (Primary)
- Indications Community-acquired pneumonia
- Focus Therapeutic Use
- Sponsors SIMR Biotech
Most Recent Events
- 12 Feb 2025 Planned End Date changed from 10 Oct 2025 to 30 Oct 2025.
- 12 Feb 2025 Planned primary completion date changed from 2 Sep 2025 to 15 Oct 2025.
- 03 Sep 2024 New trial record